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Background: The complex aetiology of most mental disorders involves gene-environment interactions that may
operate using epigenetic mechanisms particularly DNA methylation. It may explain many of the features seen in
mental disorders including transmission, expression and antipsychotic treatment responses. This report deals with
the assessment of DNA methylation in response to an antipsychotic drug (olanzapine) on brain (cerebellum and
hippocampus), and liver as a non-neural reference in a rat model. The study focuses on the Cadherin/protocadherins
encoded by a multi-gene family that serve as adhesion molecules and are involved in cell-cell communication in the
mammalian brain. A number of these molecules have been implicated in the causation of schizophrenia and related
disorders.
Results: The results show that olanzapine causes changes in DNA methylation, most specific to the promoter region of
specific genes. This response is tissue specific and involves a number of cadherin genes, particularly in cerebellum. Also,
the genes identified have led to the identification of several pathways significantly affected by DNA methylation in
cerebellum, hippocampus and liver. These included the Gα12/13 Signalling (p = 9.2E-08) and Wnt signalling (p = 0.01)
pathways as contributors to psychosis that is based on its responsiveness to antipsychotics used in its treatment.
Conclusion: The results suggest that DNA methylation changes on the promoter regions of the Cadherin/
protocadherin genes impact the response of olanzapine treatment. These impacts have been revealed through the
identified pathways and particularly in the identification of pathways that have been previously implicated in psychosis.Background
Cadherins are involved in neurodevelopment, nerve cell
migration and cell-to-cell interaction and therefore it
follows that they may regulate the pathogenesis of psy-
chosis [1]. For example, previous studies suggested the
importance of investigating epigenetic control of PcdhXY
with respect to psychiatric disorders [2]. Interestingly,
previous studies have suggested that epigenetic modifica-
tions regulate the expression of clustered protocadherin
genes (Pcdhs) [3]. In mammals, more than 50 Pcdh genes
are categorized into three clusters Pcdh-α, Pcdh-β and
Pcdh-γ encoding diversified proteins mainly expressed in
the nervous system [3-5]. Some protocadherins (Pcdh1* Correspondence: ssingh@uwo.ca
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unless otherwise stated.and Pcdh7) are regulated by Methyl-CpG-binding protein,
MeCP2, which is a protein that is strongly associated with
epigenetic regulation [6].
Aberrant promoter methylation of cadherin family
genes has been implicated in complex human disorders
[7]. For example, Pcdh10, a novel tumor suppresser gene
is found to be downregulated by hypermethylation in
various cancer cases [8-10] corroborating the evidence
that epigenetics plays a role in complex disorders. Fur-
ther, the high expression of Pcdhαv8 in mouse neuro-
blastoma cell lines was found to be associated with
demethylation of the 5’ regulatory region of the gene
[11]. In the same study, a dynamic change in methyla-
tion of Pcdh genes was observed. The 5’ region of the
Pcdhαv4 gene was 99% methylated in neuroblastoma
cells and ~35% methylated in the cortex of mice. On
the contrary, the 5’ region of the Pcdhαv8 was reported
to be 99.1-100% methylated in neuroblastoma cell linestd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
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C57BL/6 [11].
Although it is possible that aberrant metabolomics
may be due to mutation in a single gene or be the effect
of a single environment, emerging literature argues that
most often the development of complex diseases and
disorders represents a complex interaction of multiple
genes and multiple environments [12]. This is true in
most behavioral disorders that have complex aetiology
involving several genes and environment [13]. Ultim-
ately, the two contributors enact their effect by altering
cellular metabolomics through changes in gene expres-
sion via epigenetic modifications such as DNA methyla-
tion [14]. However, an assessment of the mechanistic
basis of the effect of environment has been arduous as
an environment may cause aberration via its effect on
the gene(s). This offers renewed hope for the treatment
of complex disorders, as it may be possible to manipu-
late DNA methylation, and subsequently alter gene ex-
pression to affect metabolomic aberrations and facilitate
a cure or decreased severity of symptoms. Also, this
paradigm of disease causation is expected to be instru-
mental in identifying mechanisms of actions of antipsy-
chotics, such as olanzapine.
Mental disorders including psychosis are difficult to
treat. Antipsychotics have variable responses and their
mechanism of action is imprecise. We have assessed the
mechanisms of action of olanzapine, a commonly used
antipsychotic medication. The results argue that olanza-
pine may improve the mental outcome of patients by al-
tering the methylation profile of genes implicated in
disease-specific pathways. Specifically, our studies re-
ported changes in the methylation of genes implicated in
the dopamine pathways in the hippocampus and cerebel-
lum in a rat model [15]. Interestingly, in a genome-wide
assessment, our studies showed methylation changes in
the genes of a number of pathways that may alter metabo-
lomics leading to the efficacy as well as side effects of
olanzapine [15]. These results offer a novel paradigm to
reveal critical genes and pathways by identifying changes
in methylation in response to drugs that offer relief or cure
for the disease symptoms. Here we will present data on
genes of the cadherin and protocadherin (Pcdh) family
that are preferentially affected by olanzapine. The clus-
tered protocadherin (Pcdh) genes [16] encode a group of
diverse cadherin-related transmembrane proteins, and are
expressed in the brain [17]. They generate vast single-cell
diversity in the brain [18]. They represent Ca2
+-dependent
cell adhesion molecules that are critical in vertebrate ner-
vous development [19] and maintenance of neural cir-
cuitry [20]. The expression of this cluster of genes is
regulated by a complex mechanism at the level of tran-
scription [21] that may include gene specific DNA methy-
lation [22]. Given the critical role of cadherins in braindevelopment and function it is not surprising that
genome-wide analysis for a number of mental disorders
have implicated defects in cadherin genes. These include
complex disorders, such as intellectual disability [23] aut-
ism [24] schizophrenia [25,26] and bipolar disorders [27].
This report adds to this complex literature suggesting that
a commonly used antipsychotic drug, olanzapine, affects
methylation of the promoter regions of cadherin family
genes in the rat brain. The effect of olanzapine is tissue
specific, particularly affecting several gene promoters in




Adult male Sprague-Dawley rats of 12 weeks of age (250 -
300 g) were purchased from Charles River, PQ, Canada.
Upon arrival, rats were placed (2 per cage) in standard
acrylic cages and subjected to the treatment protocol.
They housed in controlled humidity and temperature on a
12-hour light/dark cycle (lights on at 7:00 a.m.). They were
fed standard rat chow (LabDiet) and tap water ad libitum.
Ethical approval
The Institutional Animal Care Committee of the Univer-
sity of Western Ontario had approved all animal-related
procedures used in this study following the Canadian
and National Institute of Health Guides on animal ex-
perimentation. Also, the manuscript reporting followed
the ARRIVE (Animal Research: Reporting of In Vivo Ex-
periments) guidelines.
Olanzapine treatment
Before the commencement of olanzapine treatment, ani-
mals were weighed and divided into two treatment
groups with comparable means of weight. Their stress-
induced locomotor activity (following a 5 min tail pinch)
was recorded for 30 min using an automated open-field
activity chamber (San Diego Instruments, San Diego,
CA, USA). A computer that detects the disruption of
photocell beams recorded the number of beam breaks
per five minutes for half an hour as the animal moves.
Rats then received injections of olanzapine (Zyprexa,
Lilly, IN, USA; 2.5 mg/kg, i.m.; n = 8) or vehicle (phos-
phate buffered saline (PBS); n = 8) between 1:30 pm and
3:00 pm daily for 19 days. On day 20, eighteen hours
after the last olanzapine/vehicle injection, rats were sub-
jected to stress-induced locomotor activity to assess the
therapeutic efficacy of chronic olanzapine. Significantly
reduced locomotor activity of olanzapine treated rats in-
dicated the therapeutic efficacy of the drug administered,
which was comparable to the dosing paradigm employed
in previous studies [28].
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Rats were decapitated without anaesthesia, brain tissues
were micro-dissected promptly in ice-cold PBS; and
three random biopsy punches through cerebellum,
hippocampus, and liver were obtained. Individual sam-
ples (three random biopsy punches of each tissue com-
posed one sample) from each rat were kept separately
and flash frozen in liquid nitrogen. The genomic DNA
was isolated from olanzapine-treated (n = 2) and saline
control (n = 2) samples of cerebellum, hippocampus and
liver. Genomic DNA was isolated from the interphase
layer of TRIzol using sodium citrate, followed by ethanol
precipitation and purification using the QIAamp® DNA
Micro Kit (QIAGEN, Valencia, CA). DNA was then
quantified using a NanoDrop ND-1000 spectrophotom-
eter (Thermo Fisher Scientific Inc., Wilmington, DE)
and all samples had OD260/OD280 nm ratios of 1.8–2.0
and OD260/OD230 nm ratios of 2.0–2.4.
Methylated DNA immunoprecipitation
This study has used methylated DNA immunoprecipita-
tion (MeDIP) to investigate genome-wide DNA methyla-
tion in a rat model [29] The MeDIP sample labeling,
hybridization, and processing were performed at Arraystar
Inc. (Rockville, Maryland, USA). The immunoprecipitated
DNA was eluted and purified by phenol chloroform ex-
traction and ethanol precipitation. The total input and
immunoprecipitated DNA were labeled with Cy3- and
Cy5-labeled random 9-mers, respectively, and hybrid-
ized to NimbleGen RN34 Meth 3×720 K CpG plus Pro-
moter array, which is a single array design containing
all known CpG Islands annotated by UCSC and all
well-characterized RefSeq promoter regions (from about
-3.88 kb to +0.97 kb of the transcription start sites [TSSs])
covered by ~720,000 probes. Scanning was performed
with the Axon GenePix 4000B microarray scanner. There-
fore, the array design would capture the global changes in
methylation.
Data analysis involved the comparison of differentially
enriched regions between drug exposed (E) and control
(C) rats, the log2-ratio values were averaged and then used
to calculate the M’ value [M’ =Average (log2 MeDIPE/
InputE) – Average (log2 MeDIPC/InputC)] for each probe.
A NimbleScan sliding-window peak-finding algorithm was
run on this data to find the differential enrichment peaks
(DEP). Using an R script program, a hierarchical clustering
analysis was completed. The probe data matrix was ob-
tained by using PeakScores from differentially methylated
regions selected by DEP analysis. This analysis used a
“PeakScore” ≥2 to define the DEPs, which is equivalent
to the average p-value ≤0.01, for all probes within the
peak. In this study, we have specifically analyzed 17
Cadherin family genes and their methylation status in
cerebellum and hippocampus with liver as a non-neuralcell types following olanzapine treatment of experimental
rats (Table 1).
Pathway analysis of array results
The affected Cadherin family genes were then subjected
to ingenuity pathway analysis (Ingenuity System Inc, CA,
USA) [http://www.ingenuity.com/]. Transcription factor
binding sites of Cdh13 that showed increased methylation
in cerebellum were identified using CTCFBSDB 2.0 [30].
This analysis was done as a representative for all cadherin
genes affected by olanzapine-induced DNA methylation.
Results
Recently, we reported that therapeutic olanzapine causes
an increase in 1294 genes and a decrease in 565 genes in
the cerebellum of treated rats [15]. This response is tis-
sue specific and only 10% of the genes affected were
shared between cerebellum and hippocampus. With re-
spect to cadherin genes, we report that the promoter
regions of 11 Cadherin family genes have olanzapine-
induced DNA methylation changes in the cerebellum as
compared to matched controls (Table 1). Of those genes,
five showed significantly increased methylation, while six
of them showed decreased methylation (p < 0.01). In com-
parison to the results on cerebellum, three cadherin genes
(Cdh17, Cdh23, Pcdh7) had increased methylation and
one gene (Pcdhga8) showed decreased methylation in
hippocampus. Also, two cadherin genes (Cdh5 and Cdh11)
had increased methylation and two genes (Pcdhga8 and
Pcdhgb7) showed decreased methylation in the liver. The
cadherin genes in the rat genome that are affected by
olanzapine-induced DNA methylation are dispersed over
different chromosomes including chromosome 2, 3, 15,
18, 19, 20 and X.
For the identification of each methylation difference,
we compared the Manhattan plot of individual cadherin
genes. It is shown in Figure 1 using Cdh13 as a model. In
this figure, the peak of differential methylation (Figure 1A),
the genomic region of Cdh13 on the rat genome
(Figure 1B) and the sequence depicting the promoter re-
gion (Figure 1C) are shown. It has allowed us to identify
regulatory features including a CTCF binding site. As
shown in Figure 1C, the methylation changes were ob-
served in the surrounding Cs and CpGs suggesting the
global effect of olanzapine. The sequence presented in
the figure showed differential methylation, which in-
cluded the identified CTCF binding site in the promoter
region of the gene.
Next, we used pathway analysis to identify major path-
ways and systems (Table 2) that may be affected by the
observed olanzapine-induced methylation changes in the
cadherin family genes in hippocampus, cerebellum and
liver listed in Table 1. Interestingly, pathway analysis in-
volving these genes revealed the most significant pathways
Table 1 List of the Cadherin genes with their promoter regions affected by olanzapine-induced methylation
Gene name C Olz Chr Strand TSS TTS Peak to TSS Accession
Cerebellum
Pcdh7 + - 14 - 57323892 56609035 -3782 NM_001004087
Pcdh8 - + 15 - 61060741 61056993 -252 NM_022868
Pcdh9 - + 15 - 76737306 75827179 -2160 NM_001191688
Pcdha11 + - 18 + 29728602 29928030 -1925 NM_199486
Pcdha9 - + 18 + 29715234 29928031 -3346 NM_199508
Pcdhga5 + - 18 + 30600857 30754205 914 NM_001037137
Pcdh19 - + X - 121209099 1.21E + 08 -777 NM_001169129
Cdh1 + - 19 + 36442692 36512091 -92 NM_031334
Cdh13 - + 19 + 48507172 49575122 -501 NM_138889
Pcdh18 + - 2 - 138629181 1.39E + 08 -3583 NM_001100524
Cdh22 + - 3 - 156275540 1.56E + 08 94 NM_019161
Hippocampus
Pcdhga8 + - 18 + 30635032 30754205 -3889 NM_001037156
Cdh17 - + 5 + 26047221 26099173 -1218 NM_053977
Cdh23 - + 20 - 28016145 27622048 -214 NM_053644
Pcdh7 - + 14 - 57323892 56609035 -1007 NM_001004087
Liver
Pcdhgb7 + - 18 + 30660279 30754207 -1029 NM_001012215
Cdh11 - + 19 + 2225208 2382805 923 NM_053392
Cdh5 - + 19 - 816108 779349 -46 NM_001107407
Pcdhga8 + - 18 + 30635032 30754205 -3889 NM_001037156
C: Control; Olz: olanzapine treated; Chr: chromosome; +: increase in DNA methylation; -: decrease in DNA methylation.
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RhoGDI signalling (p = 4.8E-07) (Figure 2B) and Wnt/β-
catenin signalling (p = 1.2E-02) pathways (Figure 2C).
They affect molecular and cellular functions associated
with cell-to-cell signalling and interactions (p = 6.13E-04 -
3.01E-02) and may affect tissue, nervous system dynamics
and behaviour. In doing so, differential methylation of
genes involved in the pathway suggested that olanzapine
affects the physiological cadherin system (p = 6.13E-04 -
9.76E-03) (Table 2).
Discussion
Cell-cell communication is an essential feature of multi-
cellular organisms. It is particularly critical in the mam-
malian brain, where molecules involved in cell-cell
interactions such as adhesion and exchange of informa-
tion provide the foundation for neurodevelopment as
well as proper functioning of the neural network. Not
surprisingly, mammalian brain is rich in such molecules.
Also, the exceptional richness and diversity of these
molecules is often accounted for by their evolution, by
multi-gene families and by diversity of regulatory mech-
anisms. For example, adhesion molecules such as cad-
herins that constitute a super-family of transmembranereceptors and mediate Ca2+ -dependent cell to cell hemo-
philic interactions are encoded by ~100 genes in humans
[31]. Also, the organization of these genes allows differen-
tial expression including gene specific DNA methylation
and differential splicing to facilitate expression of specific
cadherins in different cells and cell types [32]. As it stands,
the molecular basis of the cadherins is still unclear. What
is known is that cells expressing a given cadherin adhere
preferentially to those expressing the same cadherin sub-
type [33]. Also, the combination of qualitative and quanti-
tative differences likely confers cell type-specific adhesion
affinities on individual cells [34]. They provide the founda-
tion for target recognition, synapse formation and signal-
ling, which are critical features of any neural network [35].
The results included in this study show that olanza-
pine affects the methylation status of the cadherin gene
promoters. Given the involvement of cadherin genes in a
number of mental disorders including psychosis, it is
understandable that several cadherin genes are differen-
tially methylated in response to olanzapine. Also, this
difference is prominent in the cerebellum that is in-
volved in cognitive processing and emotional control in-
cluding attention, executive control, language, working











Figure 1 A representative figure depicting the genomic region of Cadherin 13 gene affected by olanzapine. A) Manhattan plot showing
the significance of methylation enriched regions. Red box shows DNA methylation enriched region containing subset of CpG sites overlapping
with the promoter region of Cdh13 on Chromosome 19, in olanzapine treated cerebellum compared to control (upper panel), while there was no
methylation enriched subset of CpGs at that particular genomic region in the control cerebellum compared to treated cerebellum sample (lower
panel) B) Red box shows the gene name and the promoter region affected by olanzapine-induced DNA methylation, obtained from Rat Genome
Database, C) Part of the promoter sequence entirely affected by olanzapine-induced DNA methylation, and the CTCF binding site sequence is
highlighted in red.
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have identified that the methylation differences are spe-
cific to the promoter region of individual genes (Table 1).
Also, the sequence features of these regions contain
regulatory signals (Figure 1) and cellular metabolomics.Table 2 Top pathways, networks and molecular and cellular fu




Signalling by Rho Family GTPases
Wnt/β-catenin Signalling
Thyroid Cancer Signalling
Molecular and Cellular Functions
Cell-to-cell Signalling and interaction
Cellular movement and development
Physiological System Development and Function
Behaviour, tissue development, nervous system development and function
Top Networks
Cellular Movement, Cellular Growth and Proliferation, Cancer
*For the top canonical pathways, ratio shows the number of molecules in a given p
the total number of molecules in the pathway.The associated cellular changes are compatible with
anomalies in behavioral disorders via three specific path-
ways: Gα12/13 signalling, RhoGDI signalling and Wnt
signaling (Figure 2). Gα12/13 are units of heterotrimeric
G proteins that regulate cell processes including cellnctions identified by pathway analysis using the Cadherin






6.13E-04 - 3.01E-02 4
1.09E-03 - 2.37E-02 4
6.13E-04 - 9.76E-03 5
5
athway that suffice the DNA methylation status cut-off (p<=0.01) divided by
Figure 2 The most significant pathways identified by Ingenuity pathway analysis. A) Gα12/13 signalling (p = 9.2E-08), B) RhoGDI signalling
(p = 4.8E-07), C) Wnt/β-catenin signalling (p = 1.2E-02) significantly affected by DNA methylation of the Cadherin genes.
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change factors [37] while Rho family proteins regulate a
wide diversity of cellular processes, including adhesion,
cytokinesis, cell-cell progression, membrane trafficking and
signal transduction [38]. Interestingly, the Wnt signaling
pathway has been implicated in the pathogenesis of schizo-
phrenia [39] as well as negative symptom severity in psych-
osis [40] and it has been previously shown that E-cadherin
and β-catenin affect Wnt Signaling pathway [41]. Further,
aberrant expression of transcripts of the PCDH11X/Y gene
was reportedly implicated in anomalous cerebral asym-
metry [42]. This has led to the possibility that the variation
relating to psychosis and psychological disorders may not
only be sequence based, but may also be mediated byantipsychotic-induced epigenetic changes [39,42]. The re-
sults on olanzapine-induced differential methylation of cad-
herin genes implicated in the three pathways add further
support to this still evolving paradigm. Of special interest is
the Pcdh8 gene. It has been implicated in schizophrenia
[20] and has increased methylation both in hippocampus
and liver in this study, suggesting that the expression of the
gene is likely to be compromised due to the antipsychotic
drug. The observed hypermethylation of the gene could
potentially repress its transcription [22]. Moreover, there
are indications that epigenetic changes affect not only a
single candidate gene promoter but also intragenic se-
quences located farther from the transcriptional start sites
[43]. The observed methylation changes are tissue-specific,
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ther increased or decreased methylation) is not consistent
across tissues, suggesting the possibility that the changes in
brain tissues are likely related to the efficacy of the drug
while effects in liver may be related to the adverse conse-
quences of the drug. Olanzapine-induced DNA methylation
changes in genes involved in the identified pathways may
alter the associated network functions (Table 2). However,
further study is required to specifically analyze the effects
(on a protein level) of gene-specific methylation changes on
each identified network to unravel the specific mechanism
of action of olanzapine. Also, we acknowledge that the pre-
frontal cortex and nucleus accumbens that are also impli-
cated in psychosis [44,45] may need to be investigated for
the effect of antipsychotics on methylation, in future
studies.
Conclusion
The identified pathways suggest that olanzapine-induced
DNA methylation changes on the promoter regions of
the Cadherin/protocadherin genes may have an import-
ant role in response to olanzapine treatment in psych-
osis. Further, the approach outlined in this study may be
applied to other disorders of complex aetiology.
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